



The 9th World Congress on
CONTROVERSIES IN MULTIPLE MYELOMA (COMy)
May 11-14, 2023 - Paris, France & Online
<https://comylive.cme-congresses.com/>

Faculty disclosures report

The 2023 COMy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COMy participants. In doing so, the 2023 COMy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2023 COMy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2023 COMy Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2023 COMy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2023 COMy Congress of CME based on the CME providers of the Congress.

All 2023 COMy Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2023 COMy Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

2023 COMy Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Speakers' Bureau	S
Employee	E
Other	<i>Written as stated on submitted form</i>
Nothing to declare	<i>Written as said statement</i>

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Kenneth Anderson, USA

C Pfizer, Amgen, Astra Zeneca, Janssen, Precision Biosciences

Other *Scientific founder: C4 Therapeutics, Oncopep, Dynamic Cell, Next RNA Therapy*

Hervé Avet-Loiseau, France

Nothing to declare



CME Congresses Ltd.
Email: comy@cme-congresses.com

Contact:
Tel: +44 2035827735



The 9th World Congress on
CONTROVERSIES IN MULTIPLE MYELOMA (COMy)
May 11-14, 2023 - Paris, France & Online
<https://comylive.cme-congresses.com/>

Nizar Bahlis, Canada

H Abbvie, Amgen, Celgene/BMS, Janssen, Genentech, Pfizer, Sanofi, Karyopharm, Takeda
C Abbvie, Amgen, Celgene/BMS, Janssen, Genentech, Pfizer, Sanofi, Karyopharm, Takeda

Meral Beksac, Turkey

Nothing to declare

Joan Bladé, Spain

H Janssen, Celgene/BMS, Amgen, Janssen, Oncopeptides

Eileen Boyle, USA

Nothing to declare

Michele Cavo, Italy

H GSK, Janssen, Sanofi, Roche, Amgen, Takeda, Abbvie, BMS, Celgene

Jill Corre, France

H Sanofi, Janssen, BMS

Other *Pfizer*

Luciano Costa, USA

H BMS, Janssen, Amgen, Sanofi, Adaptive

C BMS, Janssen, Amgen, Sanofi, Adaptive

Michel Delforge, Belgium

H Amgen, BMS, Janssen, Sanofi, Stemline

Meletios Dimopoulos, Greece

H (consulting) Amgen, Beigene, Takeda, Janssen, BMS, Sanofi

Hermann Einsele, Germany

H BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis

C BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis

Thierry Facon, France

Nothing to declare

Rafael Fonseca, USA

H (consulting) Abbvie, Amgen, Bayer, BMS/Celgene, GSK, H3 Therapeutics, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, OncoTracker, Pfizer, Pharmacyclics, Regeneron, Sanofi, Takeda

Other *Scientific Advisory Board – Adaptive, Caris Life Sciences, OncoMyx and OncoTracker*

Irene Ghobrial, USA

H BMS, Takeda, Amgen, Janssen, Vor Biopharma

C BMS, Novartis, AMgen, Takeda, Sanofi, Janssen, Pfizer, Menarini, Silicon Biosystems, The Binding Site, GSK, Abbvie, Adpative, 10xGeneomics

Other *Travel, accommodations, expenses : BMS, Novartis, Takeda, Janssen; Spouse, William Savage: CEO of Disc Medicines and equity in the company*

Jean-Luc Harousseau, France

Nothing to declare



CME Congresses Ltd.
Email: comy@cme-congresses.com

Contact:
Tel: +44 2035827735



The 9th World Congress on
CONTROVERSIES IN MULTIPLE MYELOMA (COMy)
May 11-14, 2023 - Paris, France & Online
<https://comylive.cme-congresses.com/>

Nisha Joseph, USA
Nothing to declare

Shaji Kumar, USA
Nothing to declare

Alessandra Larocca, Italy
H Janssen-Cilag, BMS, Amgen, Takeda, Oncopeptides, GSK, Sanofi, Karyopharm

Xavier Leleu, France
Nothing to declare

Sagar Lonial, USA
C Amgen, Celgene, Novartis, BMS, Janssen, Abbvie, Genentech, Pfizer, Takeda
Other *Clinical trials – Janssen, Takeda, Novartis, BMS; Board of Directors w/ TG Therapeutics*

Heinz Ludwig, Austria
Nothing to declare

Florent Malard, France
H Therakos/Mallinckrodt, Janssen, Biocodex, Sanofi, Jazz, Gilead, Novartis, Astellas, BMS

Salomon Manier, France
C Abbvie, Adaptive, Amgen, Celgene/BMS, GSK, Janssen, Novartis, Oncopeptides, Regeneron, Roche, Takeda

Thomas Martin, USA
Nothing to declare

María-Victoria Mateos, Spain
H Janssen, Celgene, Takeda, Amgen, GSK, Abbvie, Pfizer, Regeneron, Roche, Sanofi, Oncopeptides

Giampaolo Merlini, Italy
Nothing to declare

Hira Mian, Canada
H Pfizer, Sanofi, Takeda, BMS, GSK, Janssen
Other *Research funding from Janssen*

Philippe Moreau, France
H Celgene, Janssen, Abbvie, Sanofi, Takeda, Amgen

Gareth Morgan, USA
Nothing to declare

Nikhil Munshi, USA
C BMS, Pfizer, Janssen, Oncopeptides, Amgen, Novartis, Takeda, Legend

Paola Neri, Canada
H BMS, Janssen, Sanofi, Pfizer
C BMS, Janssen, Sanofi, Pfizer



CME Congresses Ltd.
Email: comy@cme-congresses.com

Contact:
Tel: +44 2035827735



The 9th World Congress on
CONTROVERSIES IN MULTIPLE MYELOMA (COMy)
May 11-14, 2023 - Paris, France & Online
<https://comylive.cme-congresses.com/>

Bruno Paiva, Spain

H Amgen, Becton Dickinson, BMS, GSK, Janssen, Roche, Sanofi, Takeda
C BMS, GSK, Janssen, Roche, Sanofi, Takeda

Aurore Perrot, France

Nothing to declare

Noemi Puig, Spain

Nothing to declare

Marc Raab, Germany

C BMS, Amgen, GSK, Janssen, Sanofi, Pfizer, Abbvie, Takeda

Noopur Raje, USA

C Amgen, BMS, Janssen, Pfizer, Takeda, Abbvie, Sanofi
Other *Research funding: Bluebird Bio; Scientific Advisory: Caribou Bioscience, Immuneel*

Vincent Rajkumar, USA

Nothing to declare

Paul Richardson, USA

C Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, Secura Bio, GSK, Astra Zeneca, Janssen, Takeda
Other *Research grants: Oncopeptides, Celgene/BMS, Karyopharm, Takeda*

Jesús San Miguel, Spain

Other *Advisory boards and consulting services with my institution for Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, GSK, Karyopharm, Abbvie, Secura Bio, Regeneron*

Pieter Sonneveld, Netherlands

Other *Advisory boards: Janssen, BMS, Oncopeptides Pfizer*

Evangelos Terpos, Greece

H Amgen, BMS, GSK, Janssen, Novartis, Astra Zeneca, Pfizer, Sanofi, Takeda

Steven Treon, USA

C Beigene, Janssen

Saad Usmani, USA

C Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, TeneoBio

Elena Zamagni, Italy

H Sanofi, Roche, BMS, Pfizer, Janssen, Amgen, GSK